Algernon PharmaceuticalsCSE: AGN

Phase 2a planned: 40 ischemic stroke patients in Budapest, Hungary, led by Dr Sandor Nardai; target Q3 2025

Why it matters: Phase 2a in actual stroke patients would generate the first efficacy signal for sub-hallucinogenic DMT in neurological recovery. However, the corporate pivot to diagnostics raises questions about funding and prioritization.

Watch next: Phase 2a enrollment start confirmation; Grey Matters Health rebrand completion; funding allocation for AP-188 vs NovaScan

Actual: Jan 17, 2023

First subject dosed in Phase 1 study (NCT05559931) at Centre for Human Drug Research (CHDR), Leiden, Netherlands

Why it matters: First clinical trial of sub-hallucinogenic IV DMT for stroke/TBI. Six-hour continuous infusion design targets sustained neuroplasticity without psychedelic effects — a fundamentally different approach from acute psychedelic dosing.

Actual: Jun 1, 2023

Final (3rd) cohort dosed at highest planned single dose; all dose escalations completed successfully

Why it matters: Clean safety across all dose cohorts confirms the sub-hallucinogenic IV infusion window. Dose-proportional PK enables predictable Phase 2a dosing.

Actual: Mar 1, 2024

Phase 1 completed: 29 healthy volunteers, safe and well-tolerated across all doses; plasma levels reached neuroplasticity-associated thresholds (~35 ng/mL) without psychedelic effects

Why it matters: Critical proof-of-concept: demonstrated that therapeutic plasma concentrations for neuroplasticity can be achieved below the psychedelic threshold. This validates the sub-hallucinogenic dosing strategy central to AP-188's clinical positioning for stroke rehabilitation.

Actual: Jun 7, 2024

Phase 1 data presented at Interdisciplinary Conference on Psychedelic Research (ICPR 2024), Haarlem, Netherlands

Why it matters: Peer conference presentation builds KOL awareness and validates the sub-hallucinogenic DMT stroke hypothesis in the scientific community.

Actual: May 1, 2025

Phase 1 results published in Clinical and Translational Science (peer-reviewed journal)

Why it matters: Peer-reviewed publication provides the definitive Phase 1 data record and supports the Phase 2a protocol.

Actual: Oct 15, 2025

Company renamed from Algernon Pharmaceuticals to Algernon Health Inc.

Why it matters: Name change signals broader health focus beyond pharmaceuticals.

Actual: Mar 31, 2026

Proposed second rename to Grey Matters Health Inc. with 10:1 share consolidation; launching NovaScan Neuroimaging Clinics (Alzheimer's PET scanning diagnostics business)

Why it matters: Major corporate pivot to Alzheimer's diagnostics. The company stated it will "continue to advance legacy drug development programs" (AP-188 DMT for stroke, NP-251 Repirinast for CKD), but the primary corporate strategy has shifted. This creates funding uncertainty for Phase 2a — AP-188 may become a lower-priority legacy programme.